BioSpace News Archive

STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2021 third quarter financial results at 10:00 a.m. ET on Wednesday, February 3, 2021

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 4,166,667 American Depositary Shares

LabMinds®, Inc., a pioneer in automation for solution preparation in life sciences, today announced that the Revo has been approved for use in a Good Manufacturing Practice (GMP) certified laboratory in a Top 10 Pharmaceutical company.

BioLineRx Ltd. announced that due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 12,500,000 American Depositary Shares of the Company, at a price to the public of $2.40 per ADS, less underwriting discounts and commissions.

Fulcrum Therapeutics, Inc. announced that it has priced an underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $11.00 per share, for total gross proceeds of $44.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Fulcrum.